MGMT gene silencing and benefit from temozolomide in glioblastoma

New England Journal of Medicine

Volumn 352, Issue 10, 2005, Pages 997-1003

  Hegi, Monika E ^a,c   Diserens, Annie Claire ^a   Gorlia, Thierry ^e   Hamou, Marie France ^a   De Tribolet, Nicolas ^a,b   Weller, Michael ^f   Kros, Johan M ^h   Hainfellner, Johannes A ^j   Mason, Warren ^k   Mariani, Luigi ^d   Bromberg, Jacoline E C ⁱ   Hau, Peter ^g   Mirimanoff, René O ^a   Cairncross, J Gregory ^l   Janzer, Robert C ^a   Stupp, Roger ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e EORTC DATA CENTER   (Belgium)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g UNIVERSITY OF REGENSBURG   (Germany)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k PRINCESS MARGARET HOSPITAL   (Canada)

^l UNIVERSITY OF CALGARY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; DACARBAZINE; DRUG DERIVATIVE;

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA METHYLATION; DNA REPAIR; EPIGENETICS; GENE SILENCING; GLIOBLASTOMA; HAZARD ASSESSMENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BRAIN TUMOR; DISEASE FREE SURVIVAL; GENETICS; MORTALITY; SURVIVAL;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA METHYLATION; GENE SILENCING; GLIOBLASTOMA; HUMANS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 20044372154     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa043331     Document Type: Article

References (23)

1. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343: 1350-4. [Erratum, N Engl J Med 2000;343: 1740.
2. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343: 1350-4. [Erratum, N Engl J Med 2000;343: 1740.
3. Hegi ME, Diserens A-C, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871-4.
4. Ochs K, Kaina B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res 2000;60:5815-24.
5. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 1996;56: 5375-9.
6. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004;4:296-307.
7. Hotta T, Saito Y, Fujita H, et al. O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol 1994;21:135-40.
8. Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996; 56:783-8.
9. Jaeckle KA, Eyre HJ, Townsend JJ, et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998;16:3310-5.
10. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16: 3851-7.
11. Silber JR, Blank A, Bobola MS, Ghatan S, Kolstoe DD, Berger MS. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 1999;5:807-14.
12. Qian XC, Brent TP. Methylation hotspots in the 5′ flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res 1997;57:3672-7.
13. Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS, Futscher BW. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 1997;17:5612-9.
14. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-7.
15. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
16. Komine C, Watanabe T, Katayama Y, Yoshino A, Yokoyama T, Fukushima T. Promoter hypermethylation of-the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 2003;13:176-84.
17. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
18. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-8.
19. Gorlia T, Stupp R, Eisenhauer EA, et al. Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM). J Clin Oncol 2004; 22:Suppl:859s. abstract.
20. Grombacher T, Mitra S, Kaina B. Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes. Carcinogenesis 1996;17:2329-36.
21. Fritz G, Tano K, Mitra S, Kaina B. Inducibility of the DNA repair gene encoding O6-methylguanine-DNA methyltransferase in mammalian cells by DNA-damaging treatments. Mol Cell Biol 1991;11:4660-8.
22. Friedman HS, Pluda J, Quinn JA, et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2000;18:3522-8.
23. Quinn JA, Weingart J, Brem H, et al. Phase I trial of temozolomide plus O6-benzylguanine in the treatment of patients with recurrent or progressive cerebral anaplastic gliomas. Prog Proc Am Soc Clin Oncol 2003;22:103. abstract.